 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5-(2-(Ethylamino)propyl)benzofuran; 1-(Benzofuran-5-yl)-N-ethylpropan-2-amine |
| Routes of administration | Oral |
| Drug class | Entactogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.285 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-EAPB, also known as5-(2-(ethylamino)propyl)benzofuran, is a potentiallyentactogenicamphetamine andbenzofuran which is structurally related to5-MAPB and5-APB. It might be predicted to show similar effects to these drugs in humans, but the pharmacology of 5-EAPB remains unstudied as of 2020.
5-EAPB is similar in structure to compounds such as5-APB which are claimed to be agonists of the5-HT2C receptor[2] as well as a triple monoamine reuptake inhibitor, however 5-EAPB is not listed as an example in this patent, and it is not yet established to what extent the activity of 5-EAPB resembles that of 5-APB.
Three people in their 30s were hospitalised after each taking approximately 500 mg of 5-EAPB, one of whom later died in hospital, whilst attending Brownstock music festival in Essex, UK on August 31, 2013.[3]
5-EAPB is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[4]
In the UK, all benzofurans are considered Class B drugs[5] and are therefore illegal.
